Tropifexor (LJN452) + Cenicriviroc (CVC)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis (NASH)
Conditions
Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Sep 11, 2018 → Oct 15, 2020
NCT ID
NCT03517540About Tropifexor (LJN452) + Cenicriviroc (CVC)
Tropifexor (LJN452) + Cenicriviroc (CVC) is a phase 2 stage product being developed by Novartis for Non-alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT03517540. Target conditions include Non-alcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03517540 | Phase 2 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis (NASH)